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Abstract CD95 ligand is a cytotoxic cytokine that induces 
apoptosis. Here we report that CD95-mediated apoptosis of 
human malignant glioma cells is associated with arachidonic acid 
(AA) release. Inhibitors of phospholipase A2, phospholipase C or 
diacylglycerol lipase have minor effects on AA release and fail to 
modulate apoptosis. Formation of two AA metabolites generated 
during CD95-dependent apoptosis is attenuated by the lipoxy-
genase inhibitor, nordihydroguaretic acid (NDGA). NDGA also 
blocks CD95 ligand-induced apoptosis. This effect is independent 
of antioxidant properties of NDGA. Lipoxygenase may thus play 
a critical role in CD95 ligand-induced apoptosis of human 
malignant glioma cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
CD95 (Fas/APO-1) and tumor necrosis factor receptor p55 
(TNF-R1) belong to the nerve growth factor (NGF) receptor 
superfamily. Activation of both receptors by their respective 
ligands, CD95 ligand and TNF, triggers apoptosis in suscep-
tible target cells [1,2]. CD95-dependent signaling involves 
FADD/MORT1 (Fas-associating protein with death domain) 
[3] which binds to an interleukin 1-converting enzyme (ICE)-
like protease, FLICE (FADD-like ICE), an upstream compo-
nent of a proteolytic cascade consisting of other proteases 
including CPP32 [4]. CD95 signaling also involves activation 
of acidic and neutral sphingomyelinase [5,6], resulting in gen-
eration of ceramide. Activation of neutral sphingomyelinase 
may be linked to cytoplasmic phospholipase A2 (cPLA2) [6,7]. 
Targets of ceramide include stress-activated protein kinase 
JNK [8], Ras [9] and ceramide-activated protein kinase [10]. 
The signaling pathways of the TNF receptor type I are 
similar and include interactions of TRADD (TNFR1-associ-
ated death domain) with FADD and TRAF2 (TNFR-associ-
ated factor 2) [11], ceramide generation through activation of 
sphingomyelinases [2], activation of ceramide-activated pro-
tein kinase [12], ICE-like proteases [13], N F K B [2], Ras [14], 
Raf-1 [15] and cPLA2 [16]. Activation of cPLA2 results in the 
release of arachidonic acid (AA) which is metabolized by lip-
oxygenases and cycloxygenases. The AA metabolites of 5-, 12-
, and 15-lipoxygenase, produced by oxidation of AA, are hy-
droperoxy-, and hydroxy-eicosatetraenoic acids, dihydroxy-, 
epoxy-eicosatrienoic acids (HPETES, HETES, DHET, 
EET), and leukotrienes. TNF toxicity of L929 fibrosarcoma 
cells involves cPLA2 [16]. The levels of cPLA2 in L929 sub-
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lines correlate with sensitivity to TNF but not with sensitivity 
to anti-human CD95 antibodies after transfection of CD95 
[17]. Further, inhibitors of AA metabolism prevent TNF tox-
icity but not that of CD95 antibodies [17]. Similarly, activa-
tion of cPLA2 is insufficient for CD95-dependent apoptosis of 
HuT78 lymphoma cells [6]. Yet, other authors concluded that 
cPLA2 did play a role in CD95 antibody-induced apoptosis of 
L929 cells expressing human CD95 [10]. The specific role of 
AA metabolites in the induction of apoptosis is unclear. Sev-
eral observations suggest a central role of lipoxygenase me-
tabolites in TNF toxicity of L929 and TA1 adipogenic cells 
[18,19]. 15-HPETE induces apoptosis in HIV-infected T cells 
[20]. 
We are interested in CD95 targeting as a novel approach of 
immunotherapy for human malignant glioma [21-23]. While 
expression of CD95 is a positive predictor of sensitivity to 
CD95-mediated apoptosis, variations in CD95 expression do 
not account for all heterogeneity of sensitivity to CD95-medi-
ated apoptosis [23]. Thus, some glioma cell lines require the 
co-exposure to CD95 ligand and inhibitors of RNA and pro-
tein synthesis for sensitization to apoptosis, indicating the 
constitutive or induced expression of labile cytoprotective pro-
teins which inhibit apoptosis. The signal transduction events 
during CD95-mediated apoptosis of human glioma cells have 
not been studied in detail. Here we examine the role of AA 
metabolism in CD95 ligand-induced apoptosis of these cells. 
AA release might be of particular interest since dexametha-
sone, an inhibitor of PLA2, attenuates CD95-mediated glioma 
cell apoptosis [21]. 
2. Materials and methods 
2.1. Chemicals 
[3H]Thymidine (185 Gbq/mmol), [5,6,8,9,11,12,14,15-3H]AA (230 
Ci/mmol) and l-stearoyl-2-[l-14C]arachidonyl-sn-glycero-3-phospho-
choline (54 mCi/mmol) were obtained from Amersham (Braun-
schweig, Germany). Quinacrine, dexamethasone, aristolochic acid, 
nordihydroguaretic acid (NDGA), indomethacin, esculetin, yV-tert-bu-
tyl-a-phenylnitrone (PBN), Superoxide dismutase (SOD), JV-acetyl-L-
cysteine and butylated hydroxytoluene were purchased from Sigma 
(St. Louis, MO). Arachidonyl trifluoromethylketone (AACOF3), 
D609 and RHC 80267 were from Biomol (Hamburg, Germany), 
2',7'-dihydrofluorescein diacetate (DCF-H2) was obtained from 
Molecular Probes (Groningen, The Netherlands). 
2.2. Cell lines and cell culture 
Human malignant glioma cell lines LN-18, LN-229 and LN-308 
were kindly provided by Dr. N. de Tribolet (Lausanne, Switzerland) 
and maintained as described [21-23]. L929 mouse fibrosarcoma cells, 
kindly provided by Prof. P.H. Krammer (Heidelberg, Germany), were 
cultured in RPMI-1640 containing 10% FCS, 100 U/ml penicillin and 
100 |ig/ml streptomycin. The murine neuroblastoma cell line Neuro-
2A was maintained in MEM supplemented with 10% FCS, 2 mM 
glutamine, 1% non-essential amino acids and penicillin/streptomycin. 
Neuro-2A cells engineered to produce soluble murine CD95 ligand 
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have been described [24]. One unit of cytotoxic activity of CD95 
ligand in Neuro-2A supernatants was defined as the activity required 
for half-maximal killing of the CD95 antibody-sensitive glioma cell 
line, LN-18 [21]. The experiments using CD95 ligand-containing 
supernatants were performed using as control the supernatant from 
pooled neo vector control cells. LN-308 cells forced to express human 
CD95 driven by the CMV promoter of the BCMGS vector have been 
described [23]. 
2.3. Flow cytometry 
CD95 expression at the cell surface was measured by flow cytom-
etry [21,23]. The expression level was calculated as the specific fluo-
rescence index (SFI) derived from the ratio of fluorescent signal ob-
tained with the specific CD95 antibody and an isotype control 
antibody. 
2.4. Assessment of viability and apoptosis 
Membrane integrity was assessed by trypan blue exclusion or LDH 
release, using a commercial LDH assay kit (Boehringer, Mannheim, 
Germany). For most cytotoxicity assays, the cells were seeded in 96-
well plates (104 cells/well) and allowed to attach for 24 h. In some 
experiments, the cells were pre-incubated with enzyme inhibitors for 
2 h and then exposed to CD95 ligand for 16 h in absence or presence 
of cycloheximide (CHX). Growth and viability were assessed by crys-
tal violet staining in most assays. Proliferation was also measured by 
[3H]thymidine incorporation. DNA fragmentation was measured by 
quantitative DNA fluorometry [25]. Formation of reactive oxygen 
species was measured in the Cytofluor 2350 plate reader (Millipore, 
Bedford, MA) at 485 nm excitation and 530 nm emission after incu-
bation of cells for 30 min with DCF-H2 (1 ug/ml) at different time 
points after exposure to CD95 ligand [26]. 
2.5. Determination of A A release 
Glioma cells seeded in 6-well plates were incubated for 24 h with 
[3H]AA, washed, and exposed to CD95 ligand. Medium samples were 
collected at specified time points, centrifuged, and radioactivity meas-
ured in a liquid scintillation counter. The cells were lysed and organ-
elles separated with differential centrifugation. 
2.6. cPLAi assay 
The cells were treated as indicated and the cPLA2 assay performed 
as described [6]. 
2.7. Extraction and thin layer Chromatographie (TLC) analysis of AA 
metabolites 
The glioma cells were labeled with [3H]AA as described above and 
stimulated with CD95 ligand (80 U/ml) in the absence or presence of 
CHX (10 |J,g/ml) for 8 h. The supernatants were centrifuged for 10 
min at 4000 rpm and lipids extracted as described [27]. Separation of 
lipids was performed using a solvent system consisting of chloroform/ 
methanol/glacial acetic acid/water (100:60:16:8, v/v). Iodine-stained 
bands comigrating with the respective standards were isolated and 
measured in a liquid scintillation counter. 
3. Results 
3.1. CD95-mediated apoptosis of human malignant glioma cells 
is associated with the release of AA 
The role of AA metabolism in CD95-mediated apoptosis of 
human malignant glioma cells was examined in three glioma 
cell lines with different patterns of sensitivity to CD95 ligand 
(Table 1). LN-18 expresses moderate levels of CD95 and is 
highly sensitive to CD95 ligand. LN-229 exhibits high expres-
sion of CD95 but is rather resistant to CD95 ligand unless co-
exposed to inhibitors of RNA and protein synthesis. LN-308 
is resistant to CD95 ligand because of little CD95 expression 
at the cell surface. LN-308 cells engineered to express high 
levels of CD95 acquire sensitivity to CD95-mediated apopto-
sis [23]. Fig. 1 illustrates that CD95 ligand-induced apoptosis 
evolves more rapidly in LN-229 than in LN-18 cells but that 
co-exposure to CHX is required for apoptosis in LN-229 cells. 
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Fig. 1. Time-dependent induction of apoptosis in human glioma 
cells by CD95 ligand. LN-18 (□) or LN-229 (o) were exposed to 
CD95 ligand (80 U/ml) in the absence (LN-18, LN-229) or presence 
(LN-229, • ) of CHX (10 ug/ml) for various length of time. Survival 
was assessed by crystal violet staining. Data are expressed as 
mean ± SD (n = 3) percentage of survival compared with controls ex-
posed to neo control supernatant without or with CHX. 
To investigate a CD95 ligand-mediated AA release, glioma 
cells labeled with [3H]AA were exposed to CD95 ligand in 
the absence or presence of CHX. Time-dependent changes 
in the levels of 3H-labeled compounds were monitored in 
the cell culture medium (supernatant) as well as in cytosolic, 
nuclear and particulate cell fractions. There was an increase in 
AA in the cell culture medium peaking at 4-8 h after exposure 
to CD95 ligand correlating with the induction of cytotoxicity : 
(i) CD95 ligand induced AA release in LN-18 cells (Fig. 2A); 
(ii) CHX cotreatment increased AA release by CD95 ligand-
treated LN-229 cells (Fig. 2D); while no AA was released 
from CD95 ligand-treated LN-308 neo cells, CD95-trans-
fected LN-308 cells, which are sensitized to CD95-mediated 
apoptosis (Table 1), were induced to release AA by CD95 
ligand (Fig. 2C). The differential quantification of radioactiv-
ity in supernatant, nucleus, cytoplasm and particulate frac-
tions revealed that radioactive AA was released from the par-
ticulate fraction (Fig. 2A). To confirm that AA release was 
not an unspecific consequence of cell death, we performed 
parallel experiments to follow the time courses for AA release, 
DNA fragmentation and trypan blue dye exclusion. We ob-
served AA release in LN-18 cells approximately 4 h before 
CD95 ligand-mediated apoptosis was detected by crystal vio-
let staining (Fig. 1) and trypan blue uptake (Fig. 2A,B). In 
LN-229 cells, AA release precedes both DNA fragmentation 
and trypan blue uptake (Fig. 2D-F). Thus, enhanced AA 
release, induction of DNA fragmentation and loss of mem-
brane integrity appear to be sequential steps during CD95-
mediated apoptosis of LN-18 and LN-229 malignant glioma 
cells, confirming that AA release does not result from non-
specific membrane damage. 
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Fig. 2. AA release during CD95-mediated apoptosis of human malignant glioma cells. A: LN-18 cells prelabeled with [3H]AA were exposed to 
CD95 ligand (80 U/ml). At the indicated times, supernatants were collected and cells lysed as described in Section 2. The radioactivity in the 
supernatant and in each cell compartment were measured in a liquid scintillation counter. B: LN-18 cells were exposed to CD95 ligand (80 U/ 
ml). DNA fragmentation and trypan blue uptake were measured as described in Section 2. Note that glioma cells, notably LN-18 cells, frag-
ment very little DNA when undergoing apoptosis, compared, e.g. with T cells [21,25]. C: LN-308 neo control cells or LN-308-CD95 clone C2 
cells were prelabeled with [3H]AA and exposed to CD95 ligand (80 U/ml). [3H]AA release was measured as in (A). D-F: LN-229 cells were ex-
posed to 80 U/ml CD95 ligand in the absence or presence of CHX (10 ug/ml). AA release (D), DNA fragmentation (E) or trypan blue uptake 
(F) were determined as described in Section 2. Data are representative and are expressed as mean±SD percentages (» = 3). 
3.2. CD95-mediated apoptosis of human malignant glioma cells 
is unaffected by phospholipase inhibitors 
The generation of AA and AA metabolites during CD95 
ligand-induced apoptosis suggested the involvement of phos-
pholipases in the death pathway. Therefore we tested whether 
inhibitors of PLA2, phospholipase C (PLC) or diacylglycerol 
lipase inhibited CD95 ligand-mediated cytotoxicity. We had 
previously noted a cytoprotective effect of the synthetic ste-
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Fig. 3. Phospholipase inhibitors fail to prevent AA release from 
CD95 ligand-treated human malignant gliomas cells. LN-18 glioma 
cells were loaded with [3H]AA, left untreated or pretreated for 2 h 
with AACOF3 (100 uM), dexamethasone (10 uM), D609 (4 ug/ml) 
or RHC 80267(125 uM), and subsequently exposed to CD95 ligand 
(80 U/ml) for 8 h in the presence of the inhibitors. AA release was 
measured as described in Section 2. Data are expressed as 
mean ± SD percentages (« = 3). 
roid, dexamethasone, a nonselective inhibitor of PLA2, on 
CD95 antibody-induced apoptosis of human glioma cells 
[21]. Quinacrine, AACOF3, dexamethasone and aristolochic 
acid were evaluated for the inhibition of PLA2. D609 and 
RHC80267 were used to inhibit PLC and diacylglycerol lipase 
(Table 2). To ensure the efficacy of the inhibitors, we per-
formed all studies in parallel with L929 cells, a model for 
the protective effect of phospholipase inhibitors from TNF-
mediated apoptosis [16,17]. Quinacrine was cytotoxic to the 
glioma cells at concentrations previously reported to block 
PLA2 activity in L929 cells [17]. None of the phospholipase 
inhibitors enhanced glioma cell survival after exposure to 
CD95 ligand. In contrast, most inhibitors attenuated TNF-a 
toxicity of L929 cells. Next we measured whether AA release 
during CD95 ligand-induced apoptosis (Fig. 2) resulted from 
PLA2 activation. Basal AA release was unaffected by AA-
COF3 and dexamethasone but decreased significantly by 
D609 and RHC80267 (P<0.05, /-test), suggesting a role for 
PLC and diacylglycerol lipase in basal A A generation. CD95 
ligand-evoked AA release was attenuated significantly by dex-
amethasone and RHC80267 when considering drug effects on 
CD95-mediated AA release alone. However, in light of the 
decrease of basal AA release induced by RHC80267 in un-
treated cells, only dexamethasone had a significant specific 
effect on CD95-mediated AA release: absolute CD95-evoked 
increases in AA release were 110% in untreated cells, 87% 
with AACOF3, 70% with dexamethasone, 138% with D609, 
and 100% with RHC80267. Direct measurement of enzyme 
activity using 14C-labeled phosphatidylcholine revealed a 
moderate induction of PLA2 activity in L929 cells exposed 
to TNF-a but no consistent increase in glioma cells during 
CD95-mediated apoptosis (data not shown). Thus, the enzy-
matic source of AA generation in human glioma cells stimu-
lated with CD95 ligand remains obscure. 
3.3. NDGA, a lipoxygenase inhibitor, blocks CD95 
ligand-induced apoptosis of human malignant glioma cells 
To identify AA metabolites that might be involved in 
CD95-mediated apoptosis, lipids were extracted from LN-18 
and LN-229 cells exposed to CD95 ligand or CD95 ligand 
plus CHX for 8 h and separated by TLC. Two AA-related 
compounds with Rf values of 0.7 and 0.2 were specifically 
released after CD95 ligand exposure and not detected in 
supernatant obtained from control cells. Using leukotriene 
C4 as a reference chemical, one of the compounds (Rf 0.7) 
was tentatively identified as an eicosanoide. Since leukotrienes 
are derived from AA by lipoxygenases, we assessed whether 
inhibition of such enzymes would interfere with the formation 
of the two AA metabolites. Preincubation of the cells with the 
lipoxygenase inhibitor, NDGA, for 2 h prior to CD95 ligation 
resulted in an attenuated signal for both compounds, notably 
for the RfQ.l derivative. A representative experiment is shown 
in Fig. 4A,B. Two metabolites migrating at Rf of 0.7 and 0.2 
were also detected in L929 cells exposed to TNF plus CHX. 
Further, formation of these compounds was inhibited by 
NDGA (data not shown), suggesting a common pathway of 
CD95 and TNF receptor signaling. 
To examine the biological role of AA metabolites in CD95-
mediated apoptosis, we determined whether inhibitors of lip-
oxygenases or cycloxygenases prevented the cytotoxic effects 
of CD95 ligand. Both NDGA and esculetin provided protec-
tion from CD95-mediated apoptosis. In contrast, the cyclo-
oxygenase inhibitor, indomethacin, had no such effect. 
NDGA and esculetin inhibit the proliferation of glioma cells 
[28,29]. Here, complete growth arrest was not essential for the 
protective effect of NDGA since NDGA concentrations suffi-
cient for rescue from CD95 ligand-induced cytotoxicity did 
Table 1 
Differential sensitivity of LN-18, LN-229, LN-308 and CD95-transfected LN-308 human malignant glioma cells to CD95 ligand-induced apop-
tosis 
LN-18 
LN-229 
LN-308 
LN-308-CD95 
CD95 expression 
(specific fluorescence index) 
1.5 
2.5 
1.1 
6.4 
Cytotoxicity of CD95 ligand alone 
(% survival) 
Cytotoxicity of CD95 ligand plus CHX 
(% survival) 
6±1 
91 ±3 
93 ±5 
39 ±3 
4±1 
26±2 
91±4 
22±3 
CD95 expression was assessed by flow cytometry and expressed as SFI value (see Section 2). 
For cytotoxicity assays, the glioma cells were exposed to CD95 ligand (80 U/ml) in the absence or presence of CHX (10 |ig/ml) for 16 h. 
Survival was assessed by crystal violet staining. Data are expressed as mean ± SEM of percentage of survival compared with controls exposed to 
control supernatant, or control supernatant and CHX. These data confirm and extend previously published results [21-23]. 
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not reduce proliferation in LN-229 cells as assessed by 
[3H]thymidine incorporation (Fig. 4D). Moreover, these con-
centrations of NDGA were not cytotoxic as determined by 
LDH release (Fig. 4C,D). 
NDGA is also an antioxidant [19]. However, antioxidant 
properties of NDGA were not involved in the protection of 
glioma cells from CD95-mediated apoptosis since (i) there was 
no formation of reactive oxygen species as assessed by DCF-
H2 fluorescence (data not shown) and since several antioxi-
dants, including PBN (1 mM), Superoxide dismutase (50 U/ 
ml) and JV-acetyl-L-cysteine (1 mM) failed to abrogate apop-
tosis (Table 2). In these experiments, the glioma cells were 
pretreated with the agents for 2 h and then co-incubated 
with the agents and CD95 ligand in the absence (LN-18) or 
presence (LN-229) of CHX (10 ug/ml), using concentrations 
of the antioxidants that have previously been shown to block 
potassium deprivation-induced apoptosis of cerebellar granule 
neurons in our laboratory [26]. 
4. Discussion 
Human malignant gliomas are highly aggressive neoplasms 
which result in the death of affected patients within months. 
Cultured glioma cells are rather resistant to multiple proapop-
totic stimuli including cancer chemotherapy drugs, gamma-
irradiation, and TNF. In contrast, glioma cells are not resist-
ant to CD95 ligand-induced apoptosis [21], suggesting that 
CD95 targeting may be a useful strategy to treat these tumors. 
Therefore, deciphering the signaling pathway activated during 
CD95-dependent apoptosis of glioma cells is not only of in-
terest for basic research but may have clinical implications. 
Here we report that CD95 ligand-induced apoptosis of glio-
ma cells is associated with the release of AA. The enzyme 
responsible for this AA release could not be identified. 
CD95-evoked AA release has previously been reported in 
CD95-transfected MCF-7 mammary carcinoma cells [30]. 
These authors concluded that CPLA2 was involved in the kill-
ing pathway since quinacrine and dexamethasone attenuated 
the cytotoxicity of TNF and CD95 antibodies. Similar con-
clusions were reached in a study on L929 cells expressing 
human CD95 [10]. CD95 ligation was associated with cPLA2 
induction in HuT78 lymphoma cells but that was not suffi-
cient to cause cell death [6]. We failed to obtain direct evi-
dence for CPLA2 activation after CD95 ligation in glioma 
cells. Specific inhibitors of PLA2 did not block CD95-depend-
ent AA release or apoptosis (Fig. 3). These observations sug-
gest cell type-specific cascades of CD95-mediated apoptosis. 
Whether the decrease in AA release (Fig. 3) is essential for the 
anti-apoptotic effect of dexamethasone [21], is unknown. In-
terestingly, dexamethasone also attenuates glioma cell cyto-
toxicity induced by several cancer chemotherapy drugs which 
have not been shown to kill via induction of AA generation 
[31]. 
Here we provide evidence for a critical role of a NDGA-
sensitive step during CD95 ligand-induced apoptosis of hu-
man glioma cells (Fig. 4). The link between leukotrienes and 
glioma cell toxicity is not without precedent. PLA2 -mediated 
leukotriene synthesis has been reported to induce regression of 
experimental gliomas in rats [32]. On the other hand, lipoxy-
genase inhibitors interfere with the proliferation of glioma 
cells [28,29]. The protection from CD95-mediated apoptosis 
of glioma cells by NDGA reported here did not require a 
NDGA-induced cell cycle arrest (Fig. 4). Further, although 
NDGA and esculetin are antioxidants [19], such properties 
of both chemicals were not involved here since there was no 
formation of reactive oxygen species during CD95-mediated 
Table 2 
Effects of phospholipase, lipoxygenase, cycloxygenase inhibitors and radical scavengers on CD95 ligand-induced apoptosis of human malignant 
glioma cells 
Compound 
None 
Inhibitors of CPLA2 
Quinacrine 
Aristolochic acid 
AACOF3 
Dexamethasone 
Inhibitor of PLC 
D609 
Inhibitor of diacylglycerol lipase 
RHC80267 
Lipoxygenase inhibitors 
NDGA 
Esculetin 
Cycloxygenase inhibitor 
Indomethacin 
Radical scavengers 
PBN 
SOD 
iV-acetyl-cysteine 
Butylated hydroxytoluene 
Concentration 
— 
5 uM (10 uM) 
1 mM 
100 uM 
10 uM 
4 |J,g/ml 
125 uM 
30 uM 
1 mM 
40 uM 
1 mM 
50 U/ml 
1 mM 
100 uM 
Survival 
LN-18 
(%) 
23 ±3 
8 ± 2 (toxic) 
19±3 
21±4 
35 ±3* 
25±2 
18 ± 1 
70 ±2* 
45 ±4* 
23±6 
27±1 
23±2 
22±1 
21 ± 3 
LN-229 
(%) 
22±2 
22 ± 2 (toxic) 
22±3 
18±2 
24±3 
28±3 
18±1 
102 ±1* 
46 ±4* 
21 ± 2 
21 ± 2 
23±3 
18±2 
22±4 
L929 
(%) 
18±2 
25 ±1 (35 ±1)* 
32 ±1* 
50 ±3* 
22±2 
25 ±1* 
38 ±3* 
100 ±9* 
72 ±2* 
21±2 
n.d. 
n.d. 
n.d. 
n.d. 
The glioma cells were pre-exposed to the compounds for 2 h. 
LN-18 cells were then exposed to CD95 ligand at 80 U/ml alone, LN-229 to CD95 ligand (80 U/ml) plus CHX (10 ug/ml). 
L929 cells served as a positive control for a protective effect of the inhibitors and were exposed to TNF-a (10 ng/ml) plus CHX (10 |ig/ml). 
Viability was measured by crystal violet assay at 16 h. Data are expressed as mean ± SD of percentage of survival compared with controls exposed 
to control supernatant or medium, in the absence or presence of the inhibitors or CHX (» = 3, *P<0.05, t-test, protective effect of enzyme 
inhibitor). 
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Fig. 4. NDGA inhibits CD95 ligand-induced AA metabolism and apoptosis of human malignant glioma cells. A,B : The glioma cells were la-
beled with [3H]AA. LN-18 cells were exposed to CD95 ligand (80 U/ml), LN-229 cells to CD95 ligand (80 U/ml) plus CHX (10 ug/ml), in the 
absence or presence of NDGA (30 uJVI) for 8 h. 3H-containing lipids were extracted, separated by TLC, and radioactivity measured in a liquid 
scintillation counter. A,B: AA metabolites with Rf values of 0.7 (A) and 0.2 (B). C,D: LN-18 or LN-229 cells were treated as in Fig. 1 with 
CD95 ligand alone (LN-18, (C)) or CD95 ligand plus CHX (LN-229, (D)) in the absence or presence of increasing concentrations of NDGA. 
Cytotoxicity induced by CD95 ligand, as well as [3H]thymidine incorporation and LDH release induced by NDGA alone, were measured in 
parallel as described in Section 2, at 16 h in LN-18 and at 8 h in LN-229. [3H]Thymidine labeling lasted 8 h. Data are expressed as mean±SD 
of percentage of survival, [3H]thymidine incorporation or LDH release compared with untreated controls. 
apoptosis of glioma cells and since several antioxidants failed 
to block CD95-mediated apoptosis, as previously reported for 
non-glial cells [33,34]. Fur ther studies are required to elucidate 
and dissect the subcellular biological effects of NDGA-l ike 
compounds which include at the same time prominent protec-
tion from CD95-mediated apoptosis and inhibition of prolif-
eration. 
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